{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-23-000099","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.086814+00:00","generated_at":"2026-06-12T00:26:33.021157+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeoGenomics Q2 revenue up 18% to $147M; net loss narrows 31% to $24M","bullets":["Revenue of $147M (+18% YoY); Clinical Services $123M (+17%), Advanced Diagnostics $24M (+22%).","Net loss decreased 31% to $24M; Adjusted EBITDA improved 87% to -$2M from -$16M.","Adjusted Net Loss $7M vs $20M in prior year; cash and marketable securities $409M.","FY 2023 guidance raised: revenue $565-575M, net loss $(107)-(100)M, Adjusted EBITDA $(13)-(10)M.","Pharma Services segment rebranded as Advanced Diagnostics; restructuring charges included in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-23-000099","json":"https://secwatch.observer/filing/0001077183-23-000099.json","markdown":"https://secwatch.observer/filing/0001077183-23-000099.md","text":"https://secwatch.observer/filing/0001077183-23-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000099/0001077183-23-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000099/neo-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T00:26:33.021157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b407e064d315d9d8907bc89bc9863bdca1358cf4","claim":"NEOGENOMICS INC reported second fiscal quarter of 2023 results: revenue $147 million, net income $24 million. Guidance raised.","evidence_excerpt":"as expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- NeoGenomics Reports Second Quarter 2023 Results Second Quarter Revenue Increased 18% to $147 Million Fort Myers, Florida (August 8, 2023) - NeoGenomics, Inc. (NASDAQ: NEO) (the “ Company ” ), a leading oncology testing services company, today announced its second-quarter results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000099/0001077183-23-000099-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second fiscal quarter of 2023"},{"label":"Revenue","value":"$147 million"},{"label":"Net income","value":"$24 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}